The clinical information you need, at your fingertips.

In the largest placebo-controlled PPMS trial to date, ocrelizumab reduced disability progression risk by 30%, with a 55% reduction in patients with MRI activity and a 49% reduction in those with the most advanced disability. . .

Evidence of reduced radiographic progression may help inform treatment selection for patients at risk of irreversible joint damage. . .

In dementia-free adults in their 50s and 60s, elevated Alzheimer's blood biomarkers were linked to worse processing speed and executive function and to 2-4x higher odds of steep cognitive decline over the preceding five years. . .

Imfinzi (durvalumab) added to standard Bacillus Calmette-Guerin (BCG) therapy improved disease-free survival in patients with previously untreated high-risk non-muscle invasive bladder cancer. . .

Afrezza becomes the first and only needle-free rapid-acting mealtime insulin option for patients aged 6 years and older. . .

Replacing just one to three ingredients improved nutrition while lowering meal costs by up to one-third. . .

Study links immune-mediated nerve and brain targeting to pain, dizziness, and cognitive symptoms in a subset of patients. . .

A single-cell map of 47 tissues predicts nearly every cell type can sense a hormone and most can produce one, reframing the endocrine system as distributed rather than confined to the classic glands. . .

Early data suggest AI models using routine PET/CT scans could estimate tumor and organ radiation exposure before treatment. . .